Anti-TIGIT to overcome resistance to immune checkpoint inhibitors in lung cancer: limits and potentials

In the immune checkpoint era, the clinical course of advanced or metastatic non-small-cell lung cancer (NSCLC) has remarkably improved. Treatment with immune checkpoint inhibitors (ICIs), namely anti-programmed cell death protein 1 (PD-1) and anti-programmed death-ligand 1 (PD-L1), has led to impressive long-term survival outcomes in epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) wild-type (wt) NSCLC, either as monotherapy (in the first-line setting for PD-L1 ≥50% tumors) or in combination with platinum-based chemotherapy, in both squamous and non-squamous histology.